AU2006227528B2 - Use of ADNF polypeptides for treating peripheral neurotoxicity - Google Patents
Use of ADNF polypeptides for treating peripheral neurotoxicity Download PDFInfo
- Publication number
- AU2006227528B2 AU2006227528B2 AU2006227528A AU2006227528A AU2006227528B2 AU 2006227528 B2 AU2006227528 B2 AU 2006227528B2 AU 2006227528 A AU2006227528 A AU 2006227528A AU 2006227528 A AU2006227528 A AU 2006227528A AU 2006227528 B2 AU2006227528 B2 AU 2006227528B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- ala
- leu
- pro
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012200874A AU2012200874A1 (en) | 2005-03-23 | 2012-02-15 | Use of ADNF polypeptides for treating peripheral neurotoxicity |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66490805P | 2005-03-23 | 2005-03-23 | |
| US60/664,908 | 2005-03-23 | ||
| PCT/CA2006/000438 WO2006099739A1 (en) | 2005-03-23 | 2006-03-23 | Use of adnf polypeptides for treating peripheral neurotoxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012200874A Division AU2012200874A1 (en) | 2005-03-23 | 2012-02-15 | Use of ADNF polypeptides for treating peripheral neurotoxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006227528A1 AU2006227528A1 (en) | 2006-09-28 |
| AU2006227528B2 true AU2006227528B2 (en) | 2011-05-26 |
Family
ID=37023352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006227528A Ceased AU2006227528B2 (en) | 2005-03-23 | 2006-03-23 | Use of ADNF polypeptides for treating peripheral neurotoxicity |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7452867B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1885389A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5174653B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006227528B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2602893A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006099739A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
| US6933277B2 (en) | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
| US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
| US7427590B2 (en) * | 2001-09-12 | 2008-09-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Neurothrophic components of the ADNF I complex |
| US7960334B2 (en) * | 2003-03-12 | 2011-06-14 | Ramot At Tel-Aviv University Ltd. | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia |
| JP5174653B2 (ja) * | 2005-03-23 | 2013-04-03 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
| WO2007096859A2 (en) * | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
| WO2008084483A1 (en) | 2007-01-11 | 2008-07-17 | Ramot At Tel Aviv University Ltd. | Novel therapeutics based on tau/microtubule dynamics |
| CN101848934A (zh) * | 2007-08-24 | 2010-09-29 | 以色列特拉维夫大学拉莫特技术转移公司 | 使用nap样和sal样肽模拟物的神经保护 |
| US7998928B2 (en) * | 2007-09-14 | 2011-08-16 | The Regents Of The University Of California | Method of treatment of type-1 diabetes with a humanin analogue |
| WO2010033762A1 (en) * | 2008-09-18 | 2010-03-25 | Youssef Sari | Colivelin as a neuroprotective factor |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| EP2381955A4 (en) * | 2008-12-30 | 2013-01-16 | Univ Ramot | COMBINATION THERAPIES WITH NAP |
| EP2467397A1 (en) | 2009-08-17 | 2012-06-27 | Ramot at Tel-Aviv University Ltd. | Nap alpha-aminoisobutyric acid analog with neuroprotective activity |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| EP2521919B1 (en) | 2010-01-06 | 2015-03-04 | Ramot at Tel Aviv University, Ltd. | Method for diagnosing and monitoring schizophrenia and tauopathies |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| WO2017130190A1 (en) * | 2016-01-28 | 2017-08-03 | Ramot At Tel-Aviv University Ltd. | Novel formulation of neuroprotective peptides |
| EP3245944A1 (en) * | 2016-05-20 | 2017-11-22 | Institut Pasteur | Olfactory means for the diagnosis of neurological complications of nervous system infection |
| US11571396B2 (en) | 2019-03-23 | 2023-02-07 | Sandra Sermone | Ketamine for treatment of ADNP syndrome and sensory processing deficits |
| EP3979995A4 (en) | 2019-06-04 | 2023-07-26 | ADNP Kids Research Foundation | Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions |
| WO2022003673A1 (en) | 2020-06-30 | 2022-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Humanin analogs and uses thereof |
| US20250032580A1 (en) * | 2021-03-25 | 2025-01-30 | Ramot At Tel-Aviv University Ltd. | Use of adnf polypeptides in therapy |
| CA3213068A1 (en) | 2021-03-25 | 2022-09-29 | Ramot At Tel-Aviv University Ltd. | Compositions and articles comprising an adnf polypeptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027875A2 (en) * | 1998-11-06 | 2000-05-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Activity dependent neurotrophic factor iii (adnf iii) |
| WO2001012654A2 (en) * | 1999-08-18 | 2001-02-22 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Orally active peptides that prevent cell damage and death |
| US20030166544A1 (en) * | 2000-09-07 | 2003-09-04 | Clark Abbot F. | Use of ADNP for the treatment of glaucomatous optic neuropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740497A (en) | 1971-06-29 | 1973-06-19 | G Daniell | Artificial line bridge subscriber dial long line equipment tester |
| US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
| US5198420A (en) * | 1989-10-02 | 1993-03-30 | The General Hospital Corporation | Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome |
| US6174862B1 (en) | 1991-04-22 | 2001-01-16 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Neurotrophic peptides of activity dependent neurotrophic factor |
| US5767240A (en) | 1991-04-22 | 1998-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Activity-dependent neurotrophic factor |
| US5510264A (en) * | 1993-09-28 | 1996-04-23 | Insight Biotech Inc. | Antibodies which bind meningitis related homologous antigenic sequences |
| EP2172478A3 (en) * | 1997-02-07 | 2010-07-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Activity-dependent neurotrophic factor III (ADNF III) |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6933277B2 (en) | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| US6649411B2 (en) * | 1999-07-30 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides |
| US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
| US7427598B2 (en) * | 2000-05-31 | 2008-09-23 | The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory |
| US7427590B2 (en) * | 2001-09-12 | 2008-09-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Neurothrophic components of the ADNF I complex |
| US7960334B2 (en) * | 2003-03-12 | 2011-06-14 | Ramot At Tel-Aviv University Ltd. | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia |
| JP5174653B2 (ja) * | 2005-03-23 | 2013-04-03 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
| WO2007096859A2 (en) * | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
| CN101848934A (zh) * | 2007-08-24 | 2010-09-29 | 以色列特拉维夫大学拉莫特技术转移公司 | 使用nap样和sal样肽模拟物的神经保护 |
-
2006
- 2006-03-23 JP JP2008502205A patent/JP5174653B2/ja not_active Expired - Fee Related
- 2006-03-23 AU AU2006227528A patent/AU2006227528B2/en not_active Ceased
- 2006-03-23 EP EP06721705A patent/EP1885389A4/en not_active Withdrawn
- 2006-03-23 WO PCT/CA2006/000438 patent/WO2006099739A1/en not_active Ceased
- 2006-03-23 CA CA002602893A patent/CA2602893A1/en not_active Abandoned
- 2006-03-23 US US11/388,634 patent/US7452867B2/en not_active Expired - Lifetime
-
2008
- 2008-10-03 US US12/245,517 patent/US8143221B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027875A2 (en) * | 1998-11-06 | 2000-05-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Activity dependent neurotrophic factor iii (adnf iii) |
| WO2001012654A2 (en) * | 1999-08-18 | 2001-02-22 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Orally active peptides that prevent cell damage and death |
| US20030166544A1 (en) * | 2000-09-07 | 2003-09-04 | Clark Abbot F. | Use of ADNP for the treatment of glaucomatous optic neuropathy |
Non-Patent Citations (1)
| Title |
|---|
| Chiba, T et al., J. Neurosci. Res., 2004, Vol.78, No.4, pages 542-552 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5174653B2 (ja) | 2013-04-03 |
| CA2602893A1 (en) | 2006-09-28 |
| JP2008535805A (ja) | 2008-09-04 |
| US8143221B2 (en) | 2012-03-27 |
| WO2006099739A1 (en) | 2006-09-28 |
| EP1885389A1 (en) | 2008-02-13 |
| US20060247168A1 (en) | 2006-11-02 |
| EP1885389A4 (en) | 2012-04-04 |
| US7452867B2 (en) | 2008-11-18 |
| AU2006227528A1 (en) | 2006-09-28 |
| US20090137469A1 (en) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8143221B2 (en) | Use of ADNF polypeptides for treating peripheral neurotoxicity | |
| US12503501B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | |
| US20110053859A1 (en) | Methods to reduce the effects of sleep deprivation | |
| EP0541686A1 (en) | Tachykinin agonists for treatment of alzheimer's disease | |
| KR20240025721A (ko) | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 | |
| JP2012514011A (ja) | Napを用いる併用治療の方法 | |
| JP2010536801A (ja) | Nap様ペプチド擬似体およびsal様ペプチド擬似体を用いた神経保護法 | |
| WO2003047514A2 (en) | Reducing myelin-mediated inhibition of axon regeneration | |
| EP2212349B1 (en) | Synthetic analogues of neural regeneration peptides | |
| EP3019242B1 (en) | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist | |
| WO2013082045A1 (en) | Netrin loop peptide mimetics and uses thereof | |
| MX2009001591A (es) | Metodo para seleccionar compuestos con propiedades antiamiloides. | |
| US7572450B2 (en) | Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins | |
| JP7757322B2 (ja) | Fgfr3関連の認知欠損の処置のための方法及び医薬組成物 | |
| EP4103223A2 (en) | Platelet factors and cognitive improvement | |
| AU2012200874A1 (en) | Use of ADNF polypeptides for treating peripheral neurotoxicity | |
| CN120882734A (zh) | 用于治疗神经紊乱的肽 | |
| JP2020530846A (ja) | 方法 | |
| WO2012015910A2 (en) | Use of adnf polypeptides for treating neurodegenerative diseases | |
| US20130065825A1 (en) | Compositions and Methods for Delaying Senescence or Cell Death in Neurons | |
| EP1541166B1 (en) | Preventing cell death using segments of neural thread proteins | |
| KR20240035381A (ko) | 시냅스 전달을 강화하기 위한 sco-스폰딘-유래 폴리펩타이드 | |
| WO2025227011A1 (en) | Immunotherapy compositions and methods for treatment of tauopathy, neuroinflammation, and synaptic loss | |
| AU2002302239B2 (en) | Method of preventing cell death using segments of neural thread proteins | |
| WO1999051736A1 (en) | Neuron regulatory factor comprising a small peptide for promoting neuron survival |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |